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A new liquid chromatography /tandem mass spectrometry method
for quantification of gangliosides in human plasma
Qianyang Huang . Xiang Zhou
Aimin Zhou

. Danting Liu . Baozhong Xin . Karen Cechner . Heng Wang

Gangliosides are a subgroup of glycosphingolipids that present
abundantly in the central nervous system [1]. They generally con
sist of a mono or polysialic acid containing hydrophilic oligosac
charide moiety linked with a hydrophobic ceramide portion that
comprises a sphingosine backbone and a fatty acid chain with a
variable number of carbons. Such compounds are predominately
localized at the cellular membrane of neuronal and glial cells with
their ceramide portion embedded inward into the outer leaflet of
the lipid bilayer and the oligosaccharide moiety protruding out
ward into the extracellular matrix [2 ]. To date, more than 180 gan
glioside species with characteristic carbohydrate moieties have
been identified in vertebrates. In addition to disparate linking
arrangements among various monosaccharide units in carbohy

drate moiety, each species possesses multiple components with
the ceramide portion encompassing an alterable chain length of a
fatty acid, which implies the great structural heterogeneity of such
molecules [3] (corresponding classifications and nomenclatures
are shown in Fig. 1). The structural diversity empowers ganglia
sides with the versatility for biologically functioning as modulators
of signaling receptors in the regulation of various cellular events
such as neurotrophy and neurotransmission by physiologically
interacting with regulatory proteins in the nervous system [4].
The exact physiological role of gangliosides in the brain is not
fully understood yet, but they are believed to be functioning in
the regulation of receptor mediated cell signaling pathways, espe
cially in cell differentiation, proliferation, and death [5 8]. Such
functions turn out to be typically serving as integral components
of cell surface microdomains [9] or lipid rafts [10] along with pro
teins, sphingomyelins, and cholesterol in administering signal
events affecting neural development and contributing to the
pathogenesis of numerous clinical diseases and disorders,
including GM3 synthase deficiency (GSD) [11 13], Tay Sachs
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Fig.1. Classiﬁcation and nomenclature of basic gangliosides. Glucose residue: r; galactose residue: s, u; N-acetylgalactosamine residue: t; N-acetylneuraminic acid
residue: v, w, x, y, z, 10 .

disease [14,15], and Sandhoff disease [16 18]. GM3 synthase deﬁ
ciency is a neurological disorder recently identiﬁed among the
Amish people in the United States caused by mutation of the
GMs synthase gene, resulting in the absence of GM3 and its down
stream metabolites. The clinical manifestation of these patients is
similar to intractable seizures with profound mental and physical
retardation [11]. During recent years, studies have illustrated
aberrant ganglioside proﬁles in neurodegenerative syndromes,
implying their potential contribution to the development or
progression of these chronic and incurable neurodegenerative
disorders such as Parkinson disease [19,20] and Alzheimer disease
[21].
During past decades, measurement or proﬁling of gangliosides
in animal tissues, cultured cells, or cerebrospinal ﬂuid has been
reported using thin layer chromatography coupled with densito
metric detection [22] or immunochemical detection [23], high

performance liquid chromatography (HPLC)1 [24,25], supercritical
ﬂuid chromatography [26], and enzyme linked immunosorbent
assay [27]. These methods are subjected to limitations such as large
sample requirement, laborious sample preparation, time consuming
measurement, and insufﬁcient sensitivity and speciﬁcity. Recently,
the advent of mass spectrometry (MS) has given rise to the excellent
quantitative analysis featured by promising sensitivity and
resolution for the determination of gangliosides. Gu and coworkers
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established a method for simultaneous quantiﬁcation of GM1 and
GM2 gangliosides in human cerebrospinal ﬂuid using reverse phase
liquid chromatography (LC)/MS [28]. Sørensen reported an LC
approach interfaced with tandem mass spectrometry (MS/MS) for
the quantiﬁcation of gangliosides GD3 and GM3 in bovine milk
and infant formula [29].
In the current work, we have developed and validated an ultra
performance liquid chromatography (UPLC)/MS/MS method for the
measurement of four common ganglioside species GM2, GM3,
GD2, and GD3 in human plasma. This assay employs a simple pro
tein precipitation strategy for sample extraction, UPLC for chro
matographic separation, and MS/MS in the multiple reaction
monitoring (MRM) mode for detection to achieve high sensitivity
and speciﬁcity for rapid analysis. We successfully applied this
method to measure the four species of gangliosides in human
plasma.
Materials and methods
Materials

10 ll of 80% methanol, WS 1, and WS 2 were spiked into the vials
a, b, and c, respectively. Afterward, 10 ll of WS IS was spiked into
each of the three samples, and this set of samples was named as
spiked analyte free plasma (SAP), standard addition 1 (SA 1), and
standard addition 2 (SA 2), respectively.
For measurement of the gangliosides in unknown plasma sam
ples from normal human subjects, a similar procedure as described
above was followed except that WS QC was not added. The three
samples in each set were named as unknown plasma sample
(UPS), SA 1, and SA 2, respectively. All of the plasma samples were
extracted as described below prior to LC/MS/MS analysis.
Sample extraction
Following the plasma sample preparation, 240 ll of methanol
was added into each of them, followed by vigorous vortexing.
Then, the spiked samples were subjected to centrifugation at
14,000g for 15 min at 4 °C for protein precipitation. The superna
tants were transferred into autosampler vials with micro inserts
for LC/MS analysis.
LC/MS instrumentation

Ganglioside standards GM3 and GD3 were purchased from
Avantilipids (Alabaster, AL, USA). GM2 and GD2 ganglioside stan
dards were obtained from EMD Chemicals (Billerica, MA, USA)
and Enzo Life Sciences (Farmingdale, NY, USA), respectively. The
internal standard (IS) N omega CD3 octadecanoyl monosialogan
glioside GM3 (GM3 D3) was purchased from Matreya (Pleasant
Gap, PA, USA). HPLC grade methanol and isopropanol were
obtained from EMD Millipore (Billerica, MA, USA). Deionized water
was prepared through the Barnstead Nano PURE Water Puriﬁca
tion System (Asheville, NC, USA). Ammonium acetate was obtained
from VWR (Bridgeport, NJ, USA).

The UPLC system was composed of a DGU 20A3R degasser, two
LC 30AD pumps, an SIL 30AC autosampler, a CTO 10A column
oven, and a CBM 20A system controller from Shimadzu (Columbia,
MD, USA). The UPLC system was interfaced to a Qtrap 5500 mass
spectrometer equipped with an electrospray ionization source
and a built in Valco switch valve from AB SCIEX (Framingham,
MA, USA). The MRM mode was used for quantitation. Data acquisi
tion and chromatographic peak integration were conducted using
the Analysis 1.6.1 software package from AB SCIEX.

Human plasma

LC/MS/MS procedure

The study was approved by the DDC Clinic institutional review
board (Middleﬁeld, OH, USA), and written informed consent was
obtained from patient legal guardians. Clinical information was
collected when the patients received medical services at the DDC
Clinic. Human plasma samples were stored at 20 °C before
analysis.

After extraction, 30 ll of each sample was injected onto a Kine
tex C18 UPLC column (1.7 lm, 50  2.1 mm; Phenomenex, Tor
rance, CA, USA) guarded with a C18 Security Cartridge. The
mobile phase was a mixture of 2% methanol plus 5 mM ammonium
acetate (A) and methanol isopropanol (1:1) plus 5 mM ammo
nium acetate (B) using the gradient program shown in Table 1.
The LC ﬂow at 0.3 ml/min was introduced to the waste within
the ﬁrst 2 min and then switched to the mass spectrometer
between 2.1 and 9.0 min while all of the monitored ganglioside
components were gradually eluted out. Afterward, the LC ﬂow at
0.6 ml/min was directed to the waste again, during the column
was cleaned up and reequilibrated for the next run. The column
temperature was constantly controlled at 35 °C during the
analysis.

Stock and work solutions
Stock solutions of GM2, GM3, GD2, GD3, and IS GM3 D3 were
prepared by dissolving the original materials individually into
80% methanol to obtain a concentration of 0.25 mg/ml for each
and were stored at 20 °C before use. Three work solutions were
prepared in 80% methanol from the stock solutions to obtain gan
glioside concentrations as follows: 3, 13.6, 0.125, and 2 lg/ml (WS
QC); 4.5, 20.4, 0.125, and 3 lg/ml (WS 1); and 18, 81.6, 0.5, and
12 lg/ml (WS 2) for GM2, GM3, GD2, and GD3, respectively. The
IS stock solution also served as its work solution, named as WS
IS. These work solutions were used for preparation of spiked
plasma samples as below.
Plasma sample preparation
For method validation, known concentration samples were pre
pared by spiking ganglioside standards into the analyte free plasma
from patients with GM3 synthase deﬁciency. In brief, 30 ll of ana
lyte free plasma was transferred into each of three 0.6 ml centrifuge
vials (a, b, and c), followed by individual addition of 10 ll of WS QC
to obtain the plasma concentrations of 1.00, 4.53, 0.04, and
0.67 lg/ml for GM2, GM3, GD2, and GD3, respectively. Thereafter,

Table 1
Optimized UPLC conditions for the separation of ganglioside components.
Time (min)

B%

Flow rate (ml/min)

Stage

Valco switch valve

0
1
2
2.01
9
9.01
15.5
15.51
19.5
19.51
20.0

30
30
70
70
95
95
95
30
30
30
30

0.3

Elution

To waste

To MS
0.6

Cleanup

To waste

Equilibration
0.3

Note: A: 2% methanol + 5 mM ammonium acetate; B: methanol–isopropanol
(1:1) + 5 mM ammonium acetate.
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Calibration curve
Quantitation of the gangliosides in the SAP and UPS was imple
mented using standard addition calibration based on three levels:
one to be measured sample with nil addition and two standard
addition calibrators (SA 1 and SA 2). For each measured ganglio
side specimen, the total peak area (TPA) was obtained by summing
the individual peak area from every MRM transition channel in the
corresponding sample from a single injection.
The three level calibration curve for each ganglioside sample
was then established by plotting its normalized TPA by the IS as
the y axis versus the plasma concentration of standard addition
as the x axis. The linear regression with a weighting factor of 1/
y2 was employed. The calculation of each ganglioside plasma con
centration in a sample was conducted using the corresponding
equation obtained from the regression line as its intercept with
the x axis through extrapolation. Exempliﬁed standard addition
calibration curves for each of the four measured gangliosides from
the measurement of healthy individuals are shown in Fig. 2.

Results and discussion
Product ion mass spectra
The representative product ion mass spectra of D18:1 20:0 gan
glioside components for the four ganglioside species from added
standards are shown in Fig. 3. Apparently, fragmentation pattern
relevance can be observed within GM series and GD series, includ
ing the common product ions m/z 274 and 292 for GM series and

m/z 290 and 581 for GD series. Owing to their relatively greater
molecular masses, the singly charged ions of gangliosides are
beyond the detection ranges of our mass spectrometer and many
other commercially available triple quadruple instruments. There
fore, the selection of doubly charged precursor ions and their
appropriate daughter ions as MRM transition channels was neces
sary for quantitation in this assay.
For GD series, two proton donating carboxyl groups are
attached to their sialic acid moieties in the carbohydrate portion;
the generation of doubly charged ions had been observed to be
more favorable in the negative ionization mode than in the positive
ionization mode. For GM series that contain only one proton
donating carboxyl group, the signal responses from doubly charged
precursor ions were practically undetectable in the negative ioni
zation mode under various conditions we studied during the
method development. Because the positive mode was found to
be more effective in yielding doubly charged precursor ions from
GM2 and GM3, positive ionization was selected for determining
GM series.
After evaluating different pairs of precursor ? product ions for
quantitation, it was revealed that the following MRM transitions
provided the optimal sensitivity and selectivity: [GM2 + 2H+]2+ ?
204, [GM3 + 2H+]2+ ? 274, [GD2 2H+]2 ? 290, and [GD3
2H+]2 ? 290. The fragmentation mechanisms from the precursor
to the daughter ions are interpreted and elaborated in Fig. 4.
Selection of MRM transitions
As shown in Fig 1, each ganglioside species includes multiple
components that share the same oligosaccharide moiety but differ

Fig.2. Exempliﬁed calibration curves for GM2 (A), GM3 (B), GD2 (C), and GD3 (D) from the measurement of a healthy subject.
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Fig.3. Product ion (MS/MS) spectra for D18:1-20:0 GM2 (A), GM3 (B), GD2 (C), and GD3 (D) gangliosides.

in fatty acid chain length within their ceramide portion. For accu
rate quantitation, all of the major ganglioside components from
each ganglioside species with appreciable abundance in the plasma
and commercial standards need to be detected in the analysis.
Therefore, we ﬁrst carried out a screening study on predominant
ganglioside components of individual ganglioside species in both
normal human plasma and commercial standards using the pre
dicted MRM channels through LC/MS/MS analysis. The selected
MRM transitions corresponding to all of the signiﬁcant ganglioside
components observed by such analysis for the quantitation of the
four ganglioside species are listed in Table 2. In addition to the
quantitation MRM channels, quality assurance MRM channels with
transitions from their precursor ions to m/z 274, 292, 290, and 290
were also employed for GM2, GM3, GD2, and GD3, respectively.
Our experiments showed that the response ratio for each pair of
MRM channels was practically constant in the standard spiked sol
vent and unknown plasma extracts, conﬁrming the identity of the
monitored components.
HPLC conditions
In view of multiple MRM transitions having been exploited to
monitor each of the four ganglioside species, a sufﬁcient chromato
graphic separation between ganglioside molecules and plasma
interferences is essential to eliminate the potential ionization sup
pression inﬂuence from the matrix for the acquisition of high qual
ity quantiﬁcation during the analysis. Based on our preliminary

studies during the method development, a C18 reverse phase UPLC
column was found to provide the best resolution for multiple gan
glioside components. Under our optimized LC conditions, all of the
ganglioside components were eluted out and spread within a
retention time window from 3 to 9 min. In general, gangliosides
could be strongly retained by the C18 stationary phase due to
the hydrophobic nature of their ceramide portion. We observed
that the use of methanol isopropanol (1:1) as the solvent of
mobile phase B could elute the gangliosides from the C18 station
ary phase more effectively than the use of methanol only and could
lead to shorter chromatographic running time and better peak
shapes. The MRM chromatograms for the major components of
GM3 ganglioside are shown in Fig. 5.
It is noteworthy that the addition of 5 mM ammonium acetate
in the mobile phases considerably reinforced the peak intensities
from all MRM channels in both positive and negative ionization
modes. This experimental phenomenon can be reasonably ascribed
to ammonium acetate’s ability to stabilize the pH at the neutral
range, enabling both the proton donating interaction between
the ammonium group and gangliosides in the positive mode and
the proton accepting interaction between the acetate group and
gangliosides in the negative mode to be undertaken for the promo
tion of ionizing efﬁciency during the electrospray ionization. While
ammonium formate or formic acid was added into the mobile
phases, the responses from positive ionization was enhanced to a
certain extent, whereas substantial signal suppression occurred
in negative ionization, which was apparently attributable to the

031

m/z 290

0 0 3 : R OH
[GD2-2R+ )2
m/z 850.3

or

[GD3-2R+ J2
m/z 749.0

Fig.4. Proposed fragmentation mechanisms for 018:1-20:0 components of GM2, GM3, GD2, and GD3 gangliosides.

intensified proton donating tendency of formic acid and ammo
nium formate as compared with ammonium acetate.

Sample extractionprocedure

The most commonly used method for the isolation of ganglia
sides from biomatrices is a liquid liquid partition strategy, first
reported by Svennerholm and Fredman [30] for the treatment of
human brain samples, which was used or modified later by other
investigators [29,31,32] for extracting gangliosides from milk and
other matrices. In brief, the workflow is constructed by the follow
ing steps: (i) mixing the biomatrix with chloroform/methanol/
water (4:8:3) by vigorous shaking, (ii) transferring the ganglia
side enriched methanol/water upper phase into a new container
without disturbing the middle and lower phases, (iii) drying the
crude extract with inert gas purging, and (iv) reconstituting the
residues with methanol to a certain volume for quantitative anal
ysis. To compare the extraction recovery by using our simple pro
tein precipitation procedure and the existing extraction method,
we performed a series of parallel studies. In these assays, ana
lyte free plasmas were spiked with the gangliosides, followed by
extraction with two different extraction methods. As expected,
our protein precipitation method not only was easy to handle

and time saving, but also provided full recovery for all four gangli
aside species (Table 3). In contrast, the reported method generated
insufficient recovery for GM2 and GM3 gangliosides. According to
the literature, protein precipitation from plasma samples was com
manly conducted by the addition of 3 to 4 fold methanol or ace
tonitrile, followed by high speed centrifugation. However, the
widely adopted condition generated unsatisfactory recovery of
gangliosides from plasma. Based on modest polarity of ganglia
sides from their hydrophilic oligosaccharide moiety and hydropho
bic ceramide portion, we attempted to achieve the best extraction
recovery through adjustment of the polarity by increasing the por
tion of methanol. Nearly 100% extraction recovery was achieved for
all four ganglioside species by the addition of 8 fold methanol into
plasma for protein precipitation.

Standardadditioncalibration

According to U.S. Food and Drug Administration (FDA) guide
lines for bioanalytical method validation [33], the same type of
matrix as actual samples should be used for the preparation of
calibrators and quality controls during the quantitative method
development and validation whenever feasible concerning the
potential pronounced signal interference imposed by the complex
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Table 2
Selected MRM transitions for quantitation of the four gangtioside species.
Positive mode

Table 3

Comparison of extraction recoveries between the reported method (30) and our
protein precipitation procedure ( n • 3).

Negative mode

Species

Component

MRM
transition

Species

Component

MRM
transition

GM2

018:1-14:0
018:1-16:1
018:1-16:0
018:1-18:1
018:1-18:0
018:1-20:0
018:1-12:0
018:1-14:0
018:1-16:1
018:1-16:0
018:1-18:1
018:1-18:0
018:1-20:0
018:1-21 :0
018:1-22:0
018:1-23:0
018:1-24:0

665.1/204
678.1/204
679.1/204
692.1/204
693.1/204
707.1/204
549.3/274
563.3/274
576.3/274
577.3/274
590.3/274
591.3/274
605.3/274
612.3/274
619.3/274
626.3/274
633.3/274

CO2

018:1-14:0
018:1-16:0
018:1-18:1
018:1-18:0
018:1-19:0
018:1-20:0
018:1-21:0
018:1-22:0
018:1-12:0
018:1-14:0
018:1-15:0
018:1-16:1
018:1-16:0
018:1-17:0
018:1-18:1
018:1-18:0
018:1-19:0
018:1-20:0
018:1-21:0
018:1-22:0
018:1-23:0
018:1-24:0
018:1-25:0

808.3/290
822.3/290
835.3/290
836.3/290
843.3/290
850.3/290
857.3/290
864.3/290
693.0/290
707.0/290
714.0/290
720.0/290
721.0/290
728.0/290
734.0/290
735.0/290
742.0/290
749.0/290
756.0/290
763.0/290
770.0/290
777.0/290
784.0/290

GM3

GD3

Species Extraction recovery (%)
Protein precipitation procedure
GM2
GM3
CO2
GD3

I
l

l
I
l

j

l

'

'

A,

'

'

1

'

.l.
.!

100±8
94±7
106±9
99±5

7.83
7.93
8.69
4.98

66±6
41 ±4
103 ±5
102±9

of these studies, including determination of gangliosides in milk
and buttermilk, three or four points were used to construct the cal
ibration curves.
As indicated earlier, one of our objectives for the development
of this assay was to screen the ganglioside levels in plasma from
patients with GM3 synthase deficiency during clinical treatments.
We chose three level standard addition considering that these
patients are mostly children or even infants and could provide only
small amounts of plasma for the study. As shown in Fig. 2, the
exemplified calibration curves had R2 values in the range of
0.9998 to 1 for all four ganglioside species, demonstrating a good
linear relationship between the analyte response and concentra
tion. For the method validation, we prepared known concentration
samples by spiking ganglioside standards into aliquots of analyte
free plasma from GSD patients. Analysis of such known samples
has shown that our assay employing the three level standard addi
tion offered satisfactory precision and accuracy for the measure
ment of all the four ganglioside species in plasma, which is
detailed below.

Precisionand accuracy

The precision and accuracy for both intra and inter assays
were assessed by measuring analyte free plasma samples spiked
with the ganglioside standards in triplicate. As shown in Table 4,
the coefficient of variation (CV) for intra and inter assays of all
measured ganglioside species was within a range from 0.4 to 6%
with a relative error of less than 9%. Conclusively, the precision
GM3 018:1-12:0, mlz: 549.3/274

'

GM3 018:1-14:0, mlz: 563.3/274

'

'

'

'

'

'

'

'

'

'

'

'

'

'

GM3 018:1-16:1, mlz: 576.3/274
GM3 018:1-16:0, mlz: 577.3/274

'

'

'

'

'

' '
'

'

'

'

'

'

..

'
'

'

'

""

'

9.70
9.12
4.46
923

Note: SD, standard deviation.

matrices. For the determination of exogenous compounds that do
not present in intended matrices, the conventional standard cali
bration is usually employed to generate calibration curves based
on six or more levels of analytes spiked into analyte free matrices.
However, for the measurement of endogenous compounds that
originally present in the sample biomatrices at significant concen
trations, the standard addition calibration has been widely used for
the establishment of matrix matched calibration. Commonly, each
standard calibration curve is constructed on a set of three or four
different concentrations prepared by the addition (including a nil
addition) of known amounts of analyte standard into aliquots of
a sample to be measured. Recent publications involving the appli
cation of standard addition calibration include the quantification of
bile acids [34), sialic acids [35), gangliosides [29,.36), and other
endogenous compounds [37 39) in various biomatrices. In most

j

Reported method

Recovery (mean ±SD,%) Cl/(%) Recovery (mean ±SD,%) Cl/(%)

i
6
1

'

'

'

'

'

'

'

'

'

'

'

GM3 018:1-21:0, mlz: 612.3/274

GM3 018:1-22:0, mlz: 619.3/274

'

'

'

'

'

'

'

'

'

'

'

GM3 018:1-23:0, mlz: 626.3/274

!

GM3 018:1-24:0, mlz: 633.3/274

Fig.5. Representative chromatograms for major components of GM3 in the plasma extract from a healthy subject.
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Table 4
Intra- and inter-assay precision and accuracy for the measurement of gangliosides spiked in analyte-free human plasma from GSD patients (n = 3).
Species Spiked concentrations (lg/ml) Intra-assay

Inter-assay

Measured (mean ± SD, lg/ml) Precision (CV %) Accuracy (RE %) Measured (mean ± SD, lg/ml) Precision (CV %) Accuracy (RE %)
GM2
GM3
GD2
GD3

1.00
4.53
0.04
0.67

0.99 ± 0.025
4.45 ± 0.019
0.05 ± 0.002
0.69 ± 0.043

2.52
0.42
3.82
6.13

0.60
1.81
8.45
3.82

1.04 ± 0.059
4.60 ± 0.156
0.04 ± 0.002
0.70 ± 0.040

5.67
3.40
3.27
5.75

4.45
1.50
7.02
4.35

Note: SD, standard deviation; RE, relative error.

and accuracy of our quantitative method well fulﬁll the 15% error
and variation tolerance as required by the FDA guidelines for bio
analytical method validation [33].

Table 6
Ganglioside concentrations in plasma samples from different specimens measured by
our assay.
Subjects

Total Average levels

Stability

GM2 (mean ± GM3 (mean ± GD2 (mean ± GD3 (mean ±
SD, lg/ml)
SD, lg/ml)
SD, lg/ml)
SD, lg/ml)

The pre and post extraction stabilities of gangliosides in
plasma under various storage conditions were evaluated via the
analysis of samples prepared from the analyte free plasma spiked
with the gangliosides after undergoing the studied storage condi
tions, and the results are listed in Table 5. The stability of 4 h
pre extraction storage at room temperature was assessed by spik
ing gangliosides into the thawed analyte free plasma, letting the
spiked samples stand at room temperature for 4 h, and then ana
lyzing the samples via LC/MS immediately following the extraction
procedure. The stability of 8 h post extraction storage at room
temperature was evaluated by spiking gangliosides into analyte
free plasma, extracting the spiked samples, letting the extracts
stand at room temperature for 8 h, and then injecting them into
LC/MS for analysis. The measured stability values for the four gan
glioside species range from 86 to 110% under three different stor
age conditions: 1 month pre extraction at 20 °C, 4 h pre
extraction at room temperature, and 8 h post extraction at room
temperature. Apparently, the gangliosides were stable in the
plasma at the stages of frozen storage, sample treatment, and
analysis.
Matrix effect
The matrix effect for MS detection of gangliosides was assessed
through comparable analysis of analyte free plasma extracts
spiked with ganglioside standards and the pure solvent spiked
with such standards at the same contractions in triplicate. It was
found that the matrix impurities substantially suppressed the gan
glioside signals, and the LC/MS/MS peak areas from the plasma
extracts were only 61.3, 36.0, 68.3, and 49.0% in comparison with
the pure solvent for ganglioside GM2, GM3, GD2, and GD3, respec
tively. By using the standard addition calibration, the matrix effect
had practically no inﬂuence on the measurement because the same
matrix was used for the calibrators and the relevant samples,

Table 5
Stabilities of gangliosides in human plasma under various storage conditions (n = 3).
Stored conditions

1-month pre-extraction storage at
20 °C
4-h pre-extraction storage at room
temperature
8-h post-extraction storage at
room temperature
Note: SD, standard deviation.

Normal adults 20
GSD patients 6

2.37 ± 0.79
NM

9.72 ± 3.68
NM

0.01 ± 0.01
NM

1.80 ± 0.64
NM

Note: SD, standard deviation; NM, not measurable.

which was proven by the high linearity of calibration, precision,
and accuracy.
Method application
The validated LC/MS/MS assay was successfully applied to
determine ganglioside concentrations in human plasma from dif
ferent specimens, including 20 normal human subjects and 6
GSD patients. As shown in Table 6, the averaged ganglioside levels
in the plasma samples from 20 normal human subjects (12 male
and 8 female) were 2.37, 9.72, 0.01, and 1.80 lg/ml for GM2,
GM3, GD2, and GD3, respectively. In contrast, the analyte free
plasma from 6 patients with GSD had no gangliosides presented
at a measurable level, which was consistent with the pathological
manifestation of the neurodegenerative disorder. The averaged
GM3 concentration in plasma samples from 8 healthy human sub
jects determined by a published LC/MS method [40] was 7.2 lg/ml,
which was quite comparable to our result (9.72 lg/ml).
Conclusion
This article has detailed the development and validation of a
sensitive LC/MS/MS method for the determination of gangliosides
GM2, GM3, GD2, and GD3 in human plasma. This method used a
simple protein precipitation procedure for rapid extraction of the
gangliosides from the matrix, UPLC for high resolution chromato
graphic separation, and multiple MRM transitions for sensitive
and speciﬁc MS detection that had been successfully applied to
determine the level of gangliosides in plasma from normal human
subjects. Considering the quickness, sensitivity, and speciﬁcity of
this assay, we believe that it is also applicable to other potential
biomatrices with some appropriate modiﬁcations.

Recovery (mean ± SD, %)
GM2

GM3

GD2

GD3

104 ± 9

90.5 ± 8

84.2 ± 5

86.5 ± 4

96.3 ± 7

98.6 ± 2

86.2 ± 7

88.8 ± 6

101 ± 3

106 ± 1

106 ± 5

110 ± 6
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